TITLE

FDA actions

AUTHOR(S)
Elliott, William T.
PUB. DATE
April 2011
SOURCE
Infectious Disease Alert;Apr2011 Clinical Brief, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the drug approvals by the U.S. Food and Drug Administration (FDA). The FDA approved Spinosad for the treatment of head lice. The FDA issued an alert on the safety of the drug dronedarone (Multaq) approved for the prevention of atrial fibrillation because it has been associated with cases of severe liver injury. The FDA is opposing the use of terbutaline for the prevention or prolonged treatment of preterm labor in pregnant women because of adverse reactions including heart problems and maternal deaths.
ACCESSION #
59924424

 

Related Articles

  • FDA actions. Elliott, William T. // Neurology Alert;Apr2011 Clinical Bri, p2 

    This section offers news briefs on actions taken by the U.S. Food and Drug Administration (FDA) as of April 2011. The hydroxyprogesterone caporate injection has gained FDA approval to reduce the risk of preterm delivery before 37 weeks of pregnancy in a pregnant woman with a history of at least...

  • Immune globulin approved for primary immune deficiency disease.  // WHO Drug Information;2006, Vol. 20 Issue 1, p27 

    The article reports on the approval of Vivaglobin®, the first immune globulin product for subcutaneous injection for the prevention of serious infections in patients with primary immune deficiency diseases (PIDD), by the U.S. Food and Drug Administration. New delivery options for PIDD...

  • FDA actions.  // Clinical Cardiology Alert;Apr2011 Pharmacology, p2 

    The articles offers news briefs related to the U.S. Food and Drug Administration (FDA). A warning has been issued concerning the use of terbutaline for prevention or prolonged treatment of preterm labor in pregnant women. The FDA has approved Spinosad, a treatment for head lice. A warning...

  • Advisory panel votes against Qnexa.  // OB/GYN Clinical Alert;Sep2010 Pharmacology, p2 

    The article discusses the disapproval of the weight-loss drug Qnexa by the U.S. Food and Drug Administration (FDA) due to its side effects such as depression, sleep disorders, and other cognitive disorders.

  • MuckReads Podcast: When Diet Drugs Harm Instead of Help. Bronzan, Nicole Collins // Pro Publica;Apr2015, p1 

    The article introduces a podcast on an investigative report which found that in the last three years, the U.S. Food and Drug Administration (FDA) has approved five new drugs on the market that are potentially harmful.

  • CHEMICAL POISONING TREATMENT APPROVED FOR CHILDREN.  // Contemporary Pediatrics;Oct2010, Vol. 27 Issue 10, p22 

    The article reports on the U.S. Food and Drug Administration's approval of the drug Protopam or pralidoxime to treat pesticide poisoning in pediatric patients.

  • Lamictal XR.  // Pharmaceutical Representative;Jul2009, Vol. 39 Issue 7, p11 

    The article reports on the U.S. Food and Drug Administration's (FDA's) approval of Lamictal XR (lamotrigine) Extended-Release Tablets from GlaxoSmithKline. It notes that the drug's marketed immediate-release formulation is twice daily for epileptics. Among its side effects are dizziness,...

  • Pipeline preview.  // Formulary;May2008, Vol. 43 Issue 5, p156 

    The article provides information of various drugs approved by the U.S. Food and Drug Administration to treat diseases. Ceftobiprole from Johnson & Johnson is used to treat complicated skin and skin-structure infections. Schering-Plough has developed the drug Sugammadex to reverse the effects of...

  • This drug birds with kills two one stone. LoBuono, Charlotte // Drug Topics;3/6/2006, Vol. 150 Issue 5, p20 

    The article reports on the approval of sunitinib from Pfizer Inc. by the U.S. Food and Drug Administration for the treatment of gastrointestinal stromal tumor. Sunitinib was also granted accelerated approval for the treatment of metastatic renal cell carcinoma. Quick Family Senior Investigator...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics